Both metformin, and thiazolidinediones improve insulin resistance, but only are approved therapies for type 2 diabetes, not for insulin resistance.

If insulin resistance exists, more insulin needs to be secreted by the pancreas.

During the compensated phase on insulin resistance, insulin levels are higher, and blood glucose levels are still maintained.

High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic syndrome.

Certain drugs also may be associated with insulin resistance (e.g., glucocorticoids).

Diabetes mellitus type 2 is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency.

Metformin can reduce hirsutism, perhaps by reducing insulin resistance, and is often used if there are other features such as insulin resistance, diabetes, or obesity that should also benefit from metformin.

Insulin resistance (IR) is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin.

This is believed partly due to their effect in reducing insulin resistance.

Most patients are older, obese, sedentary, and have a degree of insulin resistance.

By contrast, growth hormone replacement therapy may be associated with increased insulin resistance.

In the presence of a higher than usual level of insulin (generally caused by insulin resistance), this down regulation acts as a kind of positive feedback, increasing the need for insulin.

A hypoglycemic response in which the two hour insulin level is higher and the blood sugar lower than fasting is consistent with insulin resistance.

The presence of insulin leads to a kind of insulin resistance every time a cell is exposed to insulin, the production of GLUT4 (type four glucose receptors) on the membrane of the cell decreases somewhat.

This normal reduction in the liver s glucose production may not occur in people with insulin resistance.

Exercise reverses this process in muscle tissue, but if it is left unchecked, it may contribute to insulin resistance.

Hypoadiponectinemia has been shown to increase insulin resistance, and is considered to be a risk factor for developing metabolic syndrome.

It is the root cause of the phenomenon known as insulin resistance and the primary process that drives chronic metabolic disease.

Fat cells have an important physiological role in maintaining triglyceride and free fatty acid levels, as well as determining insulin resistance.

The most common type of insulin resistance is associated with overweight and obesity in a condition known as the metabolic syndrome.

This may be partly due to its association with insulin resistance and obesity, but some of the increased risk appears to be independent.

Insulin resistance, which is common in obesity and is a component of syndrome X (or the metabolic syndrome), is also thought to contribute to hypertension.

Use of drugs that decrease insulin resistance, e.g., metformin and thiazolidinediones, is controversial this treatment is not approved by the U.S. Food and Drug Administration.

The food industry does precisely that, mixing more of both into the Western diet for palatability and shelf life, thereby intensifying insulin resistance and chronic metabolic disease.

There is debate regarding whether obesity or insulin resistance is the cause of the metabolic syndrome or if they are consequences of a more far reaching metabolic derangement.

Macrovesicular is the more common form of fatty degeneration, and may be caused by oversupply of lipids due to obesity, obstructive sleep apnea (OSA), insulin resistance, or alcoholism.

Fasting insulin level or GTT with insulin levels (also called IGTT).

Since this discovery, many other hormonal mechanisms have been elucidated that participate in the regulation of appetite and food intake, storage patterns of adipose tissue, and development of insulin resistance.

The onset of action of subcutaneous insulin glargine is somewhat slower than NPH human insulin.

Accompanying problems can include sweating, pressure on nerves (e.g., carpal tunnel syndrome), muscle weakness, excess sex hormone binding globulin (SHBG), insulin resistance or even a rare form of type 2 diabetes, and reduced sexual function.

The elevated insulin levels also have additional effects (see insulin) that cause further abnormal biological effects throughout the body.

A mathematical derivation known as the HOMAI, calculated from the fasting values in glucose and insulin concentrations, allows a direct and moderately accurate measure of insulin sensitivity (glucose level x insulin level 22.5).

In an insulin resistant person, normal levels of insulin do not have the same effect in controlling blood glucose levels.

Glargine insulin Sanofi Aventis developed glargine as a longer lasting insulin analogue, and markets it under the trade name Lantus.

An insulin analog is an altered form of insulin, different from any occurring in nature, but still available to the human body for performing the same action as human insulin in terms of glycemic control.

Most people do not initially need insulin.

Ghadeer's daughter Nisyona's insulin shots. Photo by author.

Inhibiting the mouse s insulin or IGF 1 receptor (daf 2) genes, or other genes needed for insulin or IGF 1 action, can extend mouse lifespan, sometimes dramatically.

The insulin, in turn, makes insulin sensitive tissues in the body (primarily skeletal muscle cells, adipose tissue, and liver) absorb glucose, and thereby lower the blood glucose level.

Resistance.

Genentech announced the production of genetically engineered human insulin in 1978.

While most body cells require the action of insulin for glucose to gain entry into the cell, the cells of the retina, kidney and nervous tissues are not insulin dependent.

See also Deep sleep therapy Electroconvulsive therapy Manfred Sakel References External links The History of Shock Therapy in Psychiatry Drug Treatment in Modern Psychiatry 1944 textbook extract on 'The Insulin Treatment of Schizophrenia' Insulin Coma Therapy by the head of the insulin coma unit at the Hillside Hospital in New York from 1952 to 1958 Shock Treatment The Killing of Susan Kelly A poem by insulin electro shock survivor Dorothy Dundas

Celebrating Resistance

Inhalable insulin was available from September 2006 to October 2007 in the United States as a new method of delivering insulin, a drug used in the treatment of diabetes, to the body.